Article: U.S. Firms Hit West German Drug Plan; Limiting Prices Called Threat to Research and Development Efforts

For years, West Germany has had one of the world's most lucrative pharmaceutical markets. With a national health plan that paid for anything doctors prescribed, West German drug prices averaged as much as 70 percent higher than those in other European countries, providing a tonic for drug firms hobbled by price restrictions in Britain and France.

At the end of this month, those days will come to an end.

In an attempt to rein in health care costs that have risen twice as fast as consumer prices in the past 20 years, the West German legislature is about to hammer out the final details on a comprehensive health reform act that will result in substantial cutbacks in the amount the West ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!